newsfilter
← Latest News
ACCESS Newswire·

Ensysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program Updates

Initiates Critical Milestone, Launching Phase 3 Trial of PF614 to Advance Next-Generation Opioid Therapy Toward Regulatory ApprovalReceives $5.3 Million Installment from NIDA To Support Overdose Protection